Jama Network
JAMA Ophthalmology : Cost-effectiveness of Aflibercept vs Bevacizumab-First Therapy for Diabetic Macular Edema
- Autor: Vários
- Narrador: Vários
- Editor: Podcast
- Duración: 0:13:02
- Mas informaciones
Informações:
Sinopsis
Interview with David W. Hutton, PhD, author of Cost-effectiveness of Aflibercept Monotherapy vs Bevacizumab First Followed by Aflibercept If Needed for Diabetic Macular Edema. Hosted by Neil Bressler, MD.
